Literature DB >> 29543675

The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study.

Alejandro A Gru1, Jinah Kim2, Melissa Pulitzer3, Joan Guitart4, Maxime Battistella5, Gary S Wood6, Lorenzo Cerroni7, Werner Kempf8, Rein Willemze9, Joya Pawade2, Christiane Querfeld10, Andras Schaffer11, Laura Pincus12, Michael Tetzlaff2, Madeleine Duvic13, Julia Scarisbrick14, Pierluigi Porcu15, Aaron R Mangold16, David J DiCaudo16, Michi Shinohara17, Eric K Hong18, Bethany Horton19, Youn H Kim18.   

Abstract

This pathology PILOT study aims to define the role and feasibility of centralized pathology review in a cohort of 75 patients from different centers in the United States and Europe using digital slide scanning. The pathologic material from 75 patients who had been diagnosed with mycosis fungoides/Sézary syndrome and were clinically staged as IIb or above was retrieved from 11 participating centers. Each pathology reviewer was provided with the pathologic diagnosis (by the referring pathologist), and the following list of histopathologic criteria (presence or absence) from the initial report: epidermotropism, folliculotropism (FT), large cell transformation, syringotropism, and granulomas. Patients with advance stage were selected for this study as this is a population where there is significant variability in the diagnosis of pathologic prognostic and predictive biomarkers. The slides were digitally scanned with an Aperio scanner and consensus review of cases occurred when major or minor discrepancies between the referral diagnosis and central pathology review occurred. Among the 75 cases, 70 (93.3%) had a final consensus diagnosis between the 3 central review pathologists. The overall agreement between the consensus review and the referring pathologist was 60%. The overall agreement was also higher between the reviewers and consensus review, compared with the referring pathologist and consensus. 65.3% of cases had some type of discrepancy (major or minor) between the outside and consensus review. Major discrepancies were seen in 34 of 73 cases (46.6%; 73 cases indicated a yes or no response). Minor discrepancies were seen in 32 of 75 (42.7%) of cases. Most of the major discrepancies were accounted by a difference in interpretation in the presence or absence of large cell transformation or FT. Most minor discrepancies were explained by a different interpretation in the expression of CD30. We found digital slide scanning to be a beneficial, reliable, and practical for a methodical approach to perform central pathology review in the context of a large clinical prospective study.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29543675      PMCID: PMC9477214          DOI: 10.1097/PAS.0000000000001041

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  26 in total

1.  Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.

Authors:  Melissa Pulitzer; Patricia L Myskowski; Steven M Horwitz; Christiane Querfeld; Brian Connolly; Janet Li; Rajmohan Murali
Journal:  Pathology       Date:  2014-12       Impact factor: 5.306

2.  Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

Authors:  Julia J Scarisbrick; H Miles Prince; Maarten H Vermeer; Pietro Quaglino; Steven Horwitz; Pierluigi Porcu; Rudolf Stadler; Gary S Wood; Marie Beylot-Barry; Anne Pham-Ledard; Francine Foss; Michael Girardi; Martine Bagot; Laurence Michel; Maxime Battistella; Joan Guitart; Timothy M Kuzel; Maria Estela Martinez-Escala; Teresa Estrach; Evangelia Papadavid; Christina Antoniou; Dimitis Rigopoulos; Vassilki Nikolaou; Makoto Sugaya; Tomomitsu Miyagaki; Robert Gniadecki; José Antonio Sanches; Jade Cury-Martins; Denis Miyashiro; Octavio Servitje; Cristina Muniesa; Emilio Berti; Francesco Onida; Laura Corti; Emilia Hodak; Iris Amitay-Laish; Pablo L Ortiz-Romero; Jose L Rodríguez-Peralto; Robert Knobler; Stefanie Porkert; Wolfgang Bauer; Nicola Pimpinelli; Vieri Grandi; Richard Cowan; Alain Rook; Ellen Kim; Alessandro Pileri; Annalisa Patrizi; Ramon M Pujol; Henry Wong; Kelly Tyler; Rene Stranzenbach; Christiane Querfeld; Paolo Fava; Milena Maule; Rein Willemze; Felicity Evison; Stephen Morris; Robert Twigger; Rakhshandra Talpur; Jinah Kim; Grant Ognibene; Shufeng Li; Mahkam Tavallaee; Richard T Hoppe; Madeleine Duvic; Sean J Whittaker; Youn H Kim
Journal:  J Clin Oncol       Date:  2015-10-05       Impact factor: 44.544

3.  Prognostic factor analysis in mycosis fungoides/Sézary syndrome.

Authors:  E Diamandidou; M Colome; L Fayad; M Duvic; R Kurzrock
Journal:  J Am Acad Dermatol       Date:  1999-06       Impact factor: 11.527

4.  Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting.

Authors:  J Guitart; J Kennedy; S Ronan; J S Chmiel; Y C Hsiegh; D Variakojis
Journal:  J Cutan Pathol       Date:  2001-04       Impact factor: 1.587

5.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.

Authors:  Nita Sally Agar; Emma Wedgeworth; Siobhan Crichton; Tracey J Mitchell; Michael Cox; Silvia Ferreira; Alistair Robson; Eduardo Calonje; Catherine M Stefanato; Elizabeth Mary Wain; Bridget Wilkins; Paul A Fields; Alan Dean; Katherine Webb; Julia Scarisbrick; Stephen Morris; Sean J Whittaker
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

6.  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Authors:  Youn H Kim; Mahkam Tavallaee; Uma Sundram; Katrin A Salva; Gary S Wood; Shufeng Li; Sima Rozati; Seema Nagpal; Michael Krathen; Sunil Reddy; Richard T Hoppe; Annie Nguyen-Lin; Wen-Kai Weng; Randall Armstrong; Melissa Pulitzer; Ranjana H Advani; Steven M Horwitz
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

7.  Transformed mycosis fungoides: clinicopathological features and outcome.

Authors:  E Barberio; L Thomas; F Skowron; B Balme; S Dalle
Journal:  Br J Dermatol       Date:  2007-06-15       Impact factor: 9.302

8.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Authors:  Julie Vose; James Armitage; Dennis Weisenburger
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

9.  Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.

Authors:  Alex F Herrera; Allison Crosby-Thompson; Jonathan W Friedberg; Gregory A Abel; Myron S Czuczman; Leo I Gordon; Mark S Kaminski; Michael M Millenson; Auayporn P Nademanee; Joyce C Niland; Scott J Rodig; Maria A Rodriguez; Andrew D Zelenetz; Ann S LaCasce
Journal:  Cancer       Date:  2014-04-04       Impact factor: 6.860

10.  New Targeted Treatments for Cutaneous T-cell Lymphomas.

Authors:  Martine Bagot
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

View more
  3 in total

1.  What factors guide treatment selection in mycosis fungoides and Sezary syndrome?

Authors:  Youn H Kim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  A Systematic Review of Clinical Characteristics and Histologic Descriptions of Acute Tubular Injury.

Authors:  Yumeng Wen; Chen Yang; Steven P Menez; Avi Z Rosenberg; Chirag R Parikh
Journal:  Kidney Int Rep       Date:  2020-08-31

3.  The Use of Screencasts with Embedded Whole-Slide Scans and Hyperlinks to Teach Anatomic Pathology in a Supervised Digital Environment.

Authors:  Mary Wong; Joseph Frye; Stacey Kim; Alberto M Marchevsky
Journal:  J Pathol Inform       Date:  2018-11-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.